Current Assets
Available For Sale Securities Debt Securities Current
Neurocrine Biosciences Available For Sale Securities Debt Securities Current increased by 36.8% to $1.05B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 40.1%, from $749.40M to $1.05B. Over 5 years (FY 2020 to FY 2025), Available For Sale Securities Debt Securities Current shows an upward trend with a 4.6% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2017
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase suggests higher liquidity and a conservative cash management strategy, while a decrease may indicate cash deployment for operations or acquisitions.
Detailed definition
This represents the portion of a company's investment portfolio consisting of debt securities that are expected to be so...
Peer comparison
Common among large-cap pharmaceutical firms maintaining significant cash reserves for R&D and M&A activities.
Metric ID:
current_assets_available_for_sale_securities_debt_securi_87ec82Historical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $516.90M | $454.80M | $370.50M | $394.70M | $485.00M | $587.20M | $726.40M | $790.80M | $816.50M | $801.40M | $780.50M | $814.30M | $899.20M | $878.90M | $843.10M | $749.40M | $711.60M | $774.60M | $767.40M | $1.05B |
| QoQ Change | — | -12.0% | -18.5% | +6.5% | +22.9% | +21.1% | +23.7% | +8.9% | +3.2% | -1.8% | -2.6% | +4.3% | +10.4% | -2.3% | -4.1% | -11.1% | -5.0% | +8.9% | -0.9% | +36.8% |
| YoY Change | — | — | — | — | -6.2% | +29.1% | +96.1% | +100.4% | +68.4% | +36.5% | +7.4% | +3.0% | +10.1% | +9.7% | +8.0% | -8.0% | -20.9% | -11.9% | -9.0% | +40.1% |
Range$370.50M – $1.05B
CAGR+16.1%
Avg YoY Growth+22.1%
Median YoY Growth+8.8%
Available For Sale Securities Debt Securities Current at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's available for sale securities debt securities current?
- Neurocrine Biosciences (NBIX) reported available for sale securities debt securities current of $1.05B in Q1 2026.
- How has Neurocrine Biosciences's available for sale securities debt securities current changed year-over-year?
- Neurocrine Biosciences's available for sale securities debt securities current increased by 40.1% year-over-year, from $749.40M to $1.05B.
- What is the long-term trend for Neurocrine Biosciences's available for sale securities debt securities current?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's available for sale securities debt securities current has grown at a 4.6% compound annual growth rate (CAGR), from $613.90M to $767.40M.
- What does available for sale securities debt securities current mean?
- Short-term investments in debt securities that the company intends to sell within a year.